BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25137018)

  • 1. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies.
    Roy R; Zurakowski D; Wischhusen J; Frauenhoffer C; Hooshmand S; Kulke M; Moses MA
    Br J Cancer; 2014 Oct; 111(9):1772-9. PubMed ID: 25137018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
    Debernardi S; O'Brien H; Algahmdi AS; Malats N; Stewart GD; Plješa-Ercegovac M; Costello E; Greenhalf W; Saad A; Roberts R; Ney A; Pereira SP; Kocher HM; Duffy S; Blyuss O; Crnogorac-Jurcevic T
    PLoS Med; 2020 Dec; 17(12):e1003489. PubMed ID: 33301466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression?
    Yip-Schneider MT; Soufi M; Carr RA; Flick KF; Wu H; Colgate CL; Schmidt CM
    Am J Surg; 2020 Mar; 219(3):492-495. PubMed ID: 31554598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imbalance of metallaproteinase/tissue inhibitors of metalloproteinase system in renal transplant recipients with chronic allograft injury.
    Mazanowska O; Kamińska D; Krajewska M; Zabińska M; Kopeć W; Boratyńska M; Chudoba P; Patrzalek D; Klinger M
    Transplant Proc; 2011 Oct; 43(8):3000-3. PubMed ID: 21996210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary extracellular matrix proteins as predictors of the severity of ureteropelvic junction obstruction in children.
    Mello MF; Thalita Dos Reis S; Kondo EY; de Bessa Júnior J; Dénes FT; Lopes RI
    J Pediatr Urol; 2021 Aug; 17(4):438.e1-438.e7. PubMed ID: 33863647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma.
    Liu QH; Shi ML; Bai J; Zheng JN
    Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer.
    Shimura T; Dagher A; Sachdev M; Ebi M; Yamada T; Yamada T; Joh T; Moses MA
    Cancer Prev Res (Phila); 2015 Mar; 8(3):240-8. PubMed ID: 25591790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.
    Roy R; Louis G; Loughlin KR; Wiederschain D; Kilroy SM; Lamb CC; Zurakowski D; Moses MA
    Clin Cancer Res; 2008 Oct; 14(20):6610-7. PubMed ID: 18927302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
    Sahni S; Pandya AR; Hadden WJ; Nahm CB; Maloney S; Cook V; Toft JA; Wilkinson-White L; Gill AJ; Samra JS; Dona A; Mittal A
    Int J Cancer; 2021 Mar; 148(6):1508-1518. PubMed ID: 33128797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine metallomics signature as an indicator of pancreatic cancer.
    Schilling K; Larner F; Saad A; Roberts R; Kocher HM; Blyuss O; Halliday AN; Crnogorac-Jurcevic T
    Metallomics; 2020 May; 12(5):752-757. PubMed ID: 32211672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
    Joergensen MT; Brünner N; De Muckadell OB
    Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
    Poruk KE; Firpo MA; Scaife CL; Adler DG; Emerson LL; Boucher KM; Mulvihill SJ
    Pancreas; 2013 Mar; 42(2):193-7. PubMed ID: 23407481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary metabolite prognostic biomarker panel for pancreatic ductal adenocarcinomas.
    Hipperson L; Hadden WJ; Nahm CB; Gill AJ; Samra JS; Dona A; Mittal A; Sahni S
    Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129966. PubMed ID: 34329704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients.
    Tian M; Cui YZ; Song GH; Zong MJ; Zhou XY; Chen Y; Han JX
    BMC Cancer; 2008 Aug; 8():241. PubMed ID: 18706098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix Metalloproteinase 11 as a Novel Tumor Promoter and Diagnostic and Prognostic Biomarker for Pancreatic Ductal Adenocarcinoma.
    Zhang X; Lu J; Zhou L; You L; Liang Z; Guo J; Zhao Y
    Pancreas; 2020 Jul; 49(6):812-821. PubMed ID: 32590618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
    Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
    BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer.
    Jenkinson C; Elliott V; Menon U; Apostolidou S; Fourkala OE; Gentry-Maharaj A; Pereira SP; Jacobs I; Cox TF; Greenhalf W; Timms JF; Sutton R; Neoptolemos JP; Costello E
    J Proteomics; 2015 Jan; 113():400-2. PubMed ID: 25316052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonhypervascular pancreatic neuroendocrine tumors: Spectrum of MDCT imaging findings and differentiation from pancreatic ductal adenocarcinoma.
    Karmazanovsky G; Belousova E; Schima W; Glotov A; Kalinin D; Kriger A
    Eur J Radiol; 2019 Jan; 110():66-73. PubMed ID: 30599875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer.
    Prokopchuk O; Grünwald B; Nitsche U; Jäger C; Prokopchuk OL; Schubert EC; Friess H; Martignoni ME; Krüger A
    BMC Cancer; 2018 Feb; 18(1):128. PubMed ID: 29394913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
    Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
    Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.